ELOXATIN (OXALIPLATIN), XELODA (CAPECITABINE) AND EPIRUBICIN (EXE) AS FIRST LINE TREATMENT IN METASTATIC GASTRIC CARCINOMA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

REZVANI HAMID; ATARIAN H.; GHADYANI M.; ABASAHL A.A.GH.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Surgery Year:2008 | Volume:16 | Issue:3 Page(s): 0-0

Download Full-Text

Persian Verion

View:

1,691

Download:

Cites:

Information Journal Paper

Title

ELOXATIN (OXALIPLATIN), XELODA (CAPECITABINE) AND EPIRUBICIN (EXE) AS FIRST LINE TREATMENT IN METASTATIC GASTRIC CARCINOMA

Author(s)

REZVANI HAMID | ATARIAN H. | GHADYANI M. | ABASAHL A.A.GH. | Issue Writer Certificate

Keywords

GASTRIC CANCERQ2

CHEMOTHERAPY REGIMENQ4

Abstract

Introduction & Objective: The combination of oxaliplatin and capecitabine has demonstrated its effect against various gastrointestinal cancers. On the other hand, Epirubicin, Cisplatin plus continuous infusion of 5-FU is widely used as a palliative regimen in patients with GASTRIC CANCER. If cisplatin is substituted by oxaliplatin and 5-FU by capecitabine, this regimen can be administered in the out patient setting, therefore we conducted this study to evaluate the effect of this first line combination in patients with metastatic GASTRIC CANCER.Materials & Methods: Twenty three patients with histologic confirmation of GASTRIC CANCER were enrolled. All patients had adequate major organ function and their PS was in the range 0-2.The Patients received 100mg/m2 Oxaliplatin intravenously on the first day and 850mg/m2 capecitabine in the first days and 60mg/m2 Epirubicin on the first day of every third week, for maximum of 8 cycles. The meximum number of given courses were 6 (1-8).Results: The response rate was 60.8% [95% confidence intervals (CI) 38.5 - 80.3%] medium PFS was 7 months and median survival was 10.6 months.The most important toxicities were as follows: anemia 45%, nausea and vomiting 10%, diarrhea 2%.Neurotoxicity grade I was seen in 10%.Conclusions: We concluded that EXE regimen every third week is a convenient and effective regimen that can easily be administrated in the outpatient setting, but this regimen needs further evaluation in large trials.

Cites

No record.

References

No record.

Cite

APA: Copy

REZVANI, HAMID, ATARIAN, H., GHADYANI, M., & ABASAHL, A.A.GH.. (2008). ELOXATIN (OXALIPLATIN), XELODA (CAPECITABINE) AND EPIRUBICIN (EXE) AS FIRST LINE TREATMENT IN METASTATIC GASTRIC CARCINOMA. IRANIAN JOURNAL OF SURGERY, 16(3), 0-0. SID. https://sid.ir/paper/398661/en

Vancouver: Copy

REZVANI HAMID, ATARIAN H., GHADYANI M., ABASAHL A.A.GH.. ELOXATIN (OXALIPLATIN), XELODA (CAPECITABINE) AND EPIRUBICIN (EXE) AS FIRST LINE TREATMENT IN METASTATIC GASTRIC CARCINOMA. IRANIAN JOURNAL OF SURGERY[Internet]. 2008;16(3):0-0. Available from: https://sid.ir/paper/398661/en

IEEE: Copy

HAMID REZVANI, H. ATARIAN, M. GHADYANI, and A.A.GH. ABASAHL, “ELOXATIN (OXALIPLATIN), XELODA (CAPECITABINE) AND EPIRUBICIN (EXE) AS FIRST LINE TREATMENT IN METASTATIC GASTRIC CARCINOMA,” IRANIAN JOURNAL OF SURGERY, vol. 16, no. 3, pp. 0–0, 2008, [Online]. Available: https://sid.ir/paper/398661/en

Related Journal Papers